Amarin Corp Plc (AMRN)

[ziploc_1]

Amarin should now focus on three doable goals
1. restore patent protection in the U.S. by expediting an introduction of a statin-EPA combo drug to the U.S. market
2. increase volume by lowering U.S. prices of Vascepa and/or introducing a low price AG into the U.S....this will help satisfy Amarin's inventory commitments and produce higher sales volumes.
3. lowering expenses by cutting back still further on marketing Vascepa in the U.S.

At this time, Amarin's focus is rightfully on Europe, but it needs to break even in the U.S. to stay afloat...The low stock price negates a secondary offering.